Bristol-Myers Squibb Co.

Total sales for Bristol-Myers Squibb’s Opdivo increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18.

Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

The S&P 500 index, tracked by the SPDR S&P 500 ETF (SPY) and the iShares Core S&P 500 ETF (IVV), rose 8.3% in October.

JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date.

Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

On October 18, Johnson & Johnson announced a fourth-quarter cash dividend of $0.90 per share for its common stock.

Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

With manufacturing slowing, a reading of the Non-Manufacturing Index at an above-neutral level (56.9) may provide some relief to the US economy, which is highly dependent on the service sector for its economic growth.

Johnson & Johnson’s (JNJ) revenues are expected to report 8.3% growth to $19.3 billion during 3Q17.

Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

In June, the FDA approved Avastin in combination with chemotherapy followed by Avastin monotherapy.

Although Johnson & Johnson stock has fallen ~3.5% in the last month, its stock has risen ~1.4% in the last year.

The FDA approved Portrazza for the treatment of squamous NSCLC based on the results of a phase III study named Squire.

For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

Johnson & Johnson (JNJ) reported revenues of $20.2 billion in 4Q17, an 11.5% growth compared to 4Q16.

Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter.

Diversified revenue streams Nektar Therapeutics’ (NKTR) total revenue includes product sales, royalty revenue, non-cash revenue related to the sale of future royalties, and license and collaboration revenue. Nektar had product sales of $4.4 million in 3Q17, compared with $144.7 million in 3Q16. Between 3Q16 and 3Q17, its royalty revenue rose from $5.5 million to $9.3 million, and its license […]

Bristol-Myers Squibb (BMY) reported a growth of 21% to $4.9 billion in its 3Q16 results.

Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

Based on prescriptions issued by cardiologists, Bristol-Myers Squibb’s and Pfizer’s Eliquis is considered the top-ranking novel anticoagulant in the US.

On June 14, XLV closed at $71.32. It was trading above its 20-day, 50-day, and 100-day moving averages. XLV’s 20-day moving average was $71.05.

Analysts expect Allergan’s second-quarter revenue to fall ~2.5% to $3.9 million compared to its revenue of $4.0 million in the second quarter of 2017.

Allergan’s International Business segment reported revenue of $864 million during the first quarter.

BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

Eli Lilly (LLY) surpassed analysts’ estimates for EPS and revenues and reported EPS of $1.05 on revenues of $5.7 billion in 3Q17.

AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

Driven by growth in Humira, Imbruvica, and Mavyret sales, AbbVie (ABBV) delivered strong Q2 2018 results on July 27.

In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

On October 4, 2016, Bristol-Myers Squibb (BMY) was trading at a forward PE (price-to-earnings) multiple of 16.8x. With products Opdivo and Yervoy, the company leads the immuno-oncology space.

23 analysts were tracking Bristol-Myers Squibb in November 2017. Six of them recommended a “strong buy” rating, while four recommended a “buy.”

In its fourth-quarter earnings investor presentation, Novartis (NVS) provided operating income guidance for two scenarios.

After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

In 1Q17, AstraZeneca (AZN) reported revenues close to $5.4 billion, which is a fall of around 12.0% on a YoY (year-over-year) basis.

Merck & Co.’s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.

With lower sales from blockbuster drugs Nexium and Seroquel, the contribution of AstraZeneca’s (AZN) Other segment fell to ~21.2% in 3Q16.

Incyte rose to one-month high price levels on May 18. Incyte opened higher on Thursday due to positive results from its lung cancer drug.

Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88.

Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

Merck (MRK), one of the largest pharmaceutical companies worldwide, reported its 1Q18 results on May 1.

Merck & Co. stock has fallen ~6.4% in 1Q18, while it’s fallen ~5.2% YTD (year-to-date) as of April 6, 2018.

Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

The price-to-earnings (or PE) multiple represents what one share can buy an equity investor.

Valeant’s (VRX) core business includes its dermatology and consumer franchise business and the acquired Bausch + Lomb and Salix Pharmaceuticals businesses.

In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million.

Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, among others.

Gilead Sciences witnessed falling revenues in the past few quarters. Its growth is expected to be revived through new products and mergers and acquisitions.

Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.

Analysts estimate Bristol-Myers Squibb will post EPS of $0.85 and revenues of $5.2 billion for 1Q18.

Bristol-Myers Squibb’s (BMY) neuroscience segment is represented by the drug Abilify, while its immuno-science segment is represented by the drug Orencia.

On June 6, Pfizer announced that it would invest ~$600 million in biotechnology and emerging growth companies through Pfizer Ventures.

Mylan’s recent commercial developments include the acquisition of the Cold-EEZE brand from ProPhase Labs and the acquisition of Meda AB.

When compared with its estimated $30.2 billion total revenue for 2016, Gilead Sciences’s (GILD) $99 billion market capitalization on November 23 seemed to be at a greater discount. GILD had a forward PE ratio of ~7.0x against its peers’ average PE of ~12.1x.

Despite patent expiries worth $2.4 billion, Novartis (NVS) managed to report a flat revenue performance in 2016.

Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.

Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

Bristol-Myers Squibb’s (BMY) Opdivo’s will now share the second-line lung cancer therapy market with Roche’s Tecentriq, along with Merck’s Keytruda.

Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

On September 26, 2016, AbbVie (ABBV) said it has submitted an application to the FDA for Imbruvica as a treatment for previously treated patients with marginal zone lymphoma.

Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment.

Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).

Merck & Co. beat Wall Street analysts’ estimates for earnings per share (or EPS) today but missed analysts’ estimates for revenues.

Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.

In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV.

Pfizer plans to use avelumab, a PD-L1 (programmed death-ligand 1) class immuno-oncology product, as a backbone therapy in its immuno-oncology programs.

Nektar Therapeutics reported its biggest fall of ~42% on June 4 after the company reported preliminary results for its phase one and phase two trials for the company’s IO (immuno-oncology) candidate

In 2Q17, Merck’s (MRK) Zepatier generated revenues of ~$517 million compared to $112 million in 2Q16.

Pfizer (PFE) reports revenue in two business segments: Innovative Health and Essential Health.

Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.

Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

With three products—Sovaldi, Harvoni, and Epclusa—in its arsenal, Gilead Sciences (GILD) dominates the HCV (hepatitis C virus) market.

Bristol-Myers Squibb stock has fallen ~1.6% in 1Q18, and its stock has fallen ~0.6% YTD (year-to-date) as of April 6, 2018.

Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.

In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.